Standard Anthracycline-based versus Docetaxel-Capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/ BIG 3-04 MINDACT phase III trial

Suzette Delaloge;Martine Piccart;Emiel Rutgers;Saskia Litière;Laura J. van ’t Veer;Franchette van den Berkmortel;Etienne Brain;Aleksandra Dudek-Peric;Miguel Gil-Gil;Patricia Gomez;Florentine S. Hilbers;Zaman Khalil;Susan Knox;Sherko Kuemmel;Georg Kunz;Anne Lesur;Jean-Yves Pierga;Peter Ravdin;Isabel T. Rubio;Mahasti Saghatchian;Tineke J. Smilde;Alastair M. Thompson;Giuseppe Viale;Gabriele Zoppoli;Peter Vuylsteke;Konstantinos Tryfonidis;Coralie Poncet;Jan Bogaerts;Fatima Cardoso

2020-01-01